Symposium 12
3月27日［土］09:45-11:15
|
| |
| |
Molecular mechanisms of heart failure
|
|
|
| |
| |
|
|
| |
我が国における心不全患者数は現在約120万人であり、すでに総人口が減少傾向にあるにもかかわらず少なくとも2035年までは増え続けると推定されている。心不全の治療は薬物治療、非薬物治療とも大変進んでいるものの、５年生存率は約60%程度と胃がんと同程度であり依然として不良である。生存率が改善しない理由は、心不全の発症機序が未解明であり、病態に基づいた治療がなされていないからである。心不全はあらゆる循環器疾患の終末像と言われるように、多くの疾患が原因となるが共通点として通常心不全発症前に心肥大を呈する。心臓は血行力学的負荷に対して心肥大を形成することによってポンプ機能を維持する。しかし長年負荷が継続すると、心肥大といった代償機序が破綻して心不全を呈する。従って心肥大から心不全に移行する機序の解明が重要となる。本シンポジウムでは、心不全の発症機序に関して、様々な視点から最新の知見をご発表いただく。
The number of heart failure patients is ~ 1.2 million in Japan and has been increasing although the total population has been decreasing. The treatments for heart failure including drugs and devices have been progressed very much, but its prognosis is still as poor as that of stomach cancer. The reason of the poor prognosis of heart failure might be lack of the treatments based on mechanisms of its development. Heart failure is a final stage of many cardiovascular diseases such as myocardial infarction, valvular diseases and hypertension. Many patients show cardiac hypertrophy before developing heart failure. Hearts are induced to form hypertrophy by hemodynamic overload to maintain its pump function, however, long-term hemodynamic overload induces the transition from cardiac hypertrophy to heart failure as a failure of the adaptation. Therefore, it is important to elucidate the molecular mechanisms of the transition. In this symposium, the cutting edge of molecular mechanisms of heart failure will be presented and discussed by a variety of aspects.
|
|
|
| |
| |
|
|
| |
| |
 |
|
Issei Komuro
Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo
|
|
 |
|
Eric N. Olson
Molecular Biology, University of Texas Southwestern Medical Center, Dallas, USA
|
|
|
| |
| |
|
|
| |
| |
|
|
Eric N. Olson
Molecular Biology, University of Texas Southwestern Medical Center, Dallas, USA
|
|
 |
|
Mikito Takefuji
Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya
|
|
|
| |
| |
 |
|
Katsuhito Fujiu
Department of Cardiovascular Medicine, The University of Tokyo, Tokyo
|
|
 |
|
Shinsuke Hanatani
Department of Cardiovascular Medicine, Kumamoto University, Kumamoto
|
|
|
| |
| |
 |
|
Toshiyuki Ko
Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo
|
|
|
|
|
|
| |
| |
|
|